MX2018010836A - Conformeros abiertos hla-b57. - Google Patents
Conformeros abiertos hla-b57.Info
- Publication number
- MX2018010836A MX2018010836A MX2018010836A MX2018010836A MX2018010836A MX 2018010836 A MX2018010836 A MX 2018010836A MX 2018010836 A MX2018010836 A MX 2018010836A MX 2018010836 A MX2018010836 A MX 2018010836A MX 2018010836 A MX2018010836 A MX 2018010836A
- Authority
- MX
- Mexico
- Prior art keywords
- hla
- open conformer
- open
- control point
- fusion protein
- Prior art date
Links
- 108010033369 HLA-B57 antigen Proteins 0.000 title abstract 6
- 108091006020 Fc-tagged proteins Proteins 0.000 abstract 2
- 239000000178 monomer Substances 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 230000002584 immunomodulator Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000029983 protein stabilization Effects 0.000 abstract 1
- 210000003289 regulatory T cell Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La invención se refiere a un confórmero abierto HLA-B57 o una proteína de fusión HLA-B57 Fc para su uso en el tratamiento o prevención de cáncer. El confórmero abierto Fc comprende o consiste en un 5 primer y un segundo monómero y cada monómero comprende una cadena HLA-B57. La proteína de fusión Fc comprende además una secuencia de polipéptido de estabilización de proteína y, opcionalmente un engarce 5 aminoácido. Otros aspectos de la invención proporcionan un medicamento combinatorio que comprende el confórmero abierto HLA-B57 Fc e inhibidores de punto de control de sistema inmunitario y/o agente agonistas de punto de control. Asimismo, la invención se refiere al uso de un confórmero abierto HLA-B57 como inmunomodulador, particularmente en enfermedades en las que la modulación de diversos componentes 10 de célula inmune (p.ej. linfocitos T CD8+ citotóxicos, Tregs) constituyen una estrategia terapéutica, p.ej., de enfermedades infecciosas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16159099 | 2016-03-08 | ||
| PCT/EP2017/055373 WO2017153438A1 (en) | 2016-03-08 | 2017-03-07 | Hla-b57 open conformers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018010836A true MX2018010836A (es) | 2019-03-28 |
| MX392624B MX392624B (es) | 2025-03-24 |
Family
ID=55586142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010836A MX392624B (es) | 2016-03-08 | 2017-03-07 | Conformeros abiertos hla-b57 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11369660B2 (es) |
| EP (2) | EP3795588B1 (es) |
| JP (1) | JP6980196B2 (es) |
| KR (1) | KR102456666B1 (es) |
| CN (1) | CN108779164B (es) |
| AU (2) | AU2017230855B2 (es) |
| BR (1) | BR112018068135A2 (es) |
| CA (1) | CA3016752C (es) |
| DK (1) | DK3426681T3 (es) |
| ES (2) | ES3009108T3 (es) |
| MX (1) | MX392624B (es) |
| WO (1) | WO2017153438A1 (es) |
| ZA (1) | ZA201805743B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4130029A1 (en) | 2021-08-05 | 2023-02-08 | ImmunOs Therapeutics AG | Pharmaceutical compositions comprising hla fusion proteins |
| KR20240045259A (ko) | 2021-08-05 | 2024-04-05 | 이뮤노스 테라퓨틱스 아게 | Hla 융합 단백질을 포함하는 약학 조성물 |
| EP4129323A1 (en) | 2021-08-05 | 2023-02-08 | ImmunOs Therapeutics AG | A modified hla-b57 with increased expression levels |
| KR20240045260A (ko) | 2021-08-05 | 2024-04-05 | 이뮤노스 테라퓨틱스 아게 | Hla 융합 단백질을 포함하는 복합 치료제 |
| WO2024165671A1 (en) | 2023-02-08 | 2024-08-15 | Immunos Therapeutics Ag | FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9810099D0 (en) * | 1998-05-11 | 1998-07-08 | Isis Innovation | Novel molecule and diagnostic method |
| US7521202B2 (en) | 1999-12-17 | 2009-04-21 | The Board Of Regents Of The University Of Oklahoma | Method and apparatus for the production of soluble MHC antigens and uses thereof |
| DE60124604T2 (de) | 2000-03-30 | 2007-09-13 | Kabushiki Kaisha Topcon | Stereobildmessvorrichtung |
| JP4102301B2 (ja) * | 2001-08-21 | 2008-06-18 | グラクソ グループ リミテッド | 薬剤過敏症反応についてのスクリーニング方法 |
| EP2292638A3 (en) * | 2002-09-27 | 2011-03-23 | Ludwig Institute For Cancer Research | MAGE-C2 antigenic peptides and uses thereof |
| CN1849395B (zh) | 2003-07-11 | 2011-04-20 | 大日本住友制药株式会社 | 来源于Livin的HLA-A24结合性癌抗原肽 |
| US7807392B1 (en) | 2003-09-15 | 2010-10-05 | Celera Corporation | Lung disease targets and uses thereof |
| WO2007011044A1 (ja) * | 2005-07-15 | 2007-01-25 | Kyushu University, National University Corporation | ジスルフィド結合型hla-g二量体を含む医薬組成物及びジスルフィド結合型hla-g二量体の製造方法 |
| US7842466B1 (en) | 2005-09-16 | 2010-11-30 | Celera Corporation | Colon disease targets and uses thereof |
| US8168586B1 (en) | 2007-11-21 | 2012-05-01 | Celera Corporation | Cancer targets and uses thereof |
| GB0821806D0 (en) | 2008-11-28 | 2009-01-07 | Circassia Ltd | Compositions with reduced dimer formation |
| CN105693861A (zh) | 2009-12-29 | 2016-06-22 | 新兴产品开发西雅图有限公司 | 异二聚体结合蛋白及其应用 |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| CN103184291A (zh) * | 2013-04-07 | 2013-07-03 | 上海血液生物医药有限责任公司 | 一种检测人hla-b*57:01等位基因的试剂盒 |
| US20160186265A1 (en) | 2013-08-15 | 2016-06-30 | Centre Hospitalier Universitarie Vaudois | Methods for Typing HLA Alleles |
| WO2015153969A1 (en) * | 2014-04-04 | 2015-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand discovery for t cell receptors |
| CN107207622B (zh) * | 2015-02-04 | 2021-09-28 | 苏黎世大学 | Hla-b27同二聚体用于癌症治疗的用途 |
-
2017
- 2017-03-07 WO PCT/EP2017/055373 patent/WO2017153438A1/en not_active Ceased
- 2017-03-07 MX MX2018010836A patent/MX392624B/es unknown
- 2017-03-07 EP EP20192762.1A patent/EP3795588B1/en active Active
- 2017-03-07 DK DK17709093.3T patent/DK3426681T3/da active
- 2017-03-07 EP EP17709093.3A patent/EP3426681B1/en active Active
- 2017-03-07 ES ES20192762T patent/ES3009108T3/es active Active
- 2017-03-07 KR KR1020187026904A patent/KR102456666B1/ko active Active
- 2017-03-07 JP JP2018547384A patent/JP6980196B2/ja active Active
- 2017-03-07 BR BR112018068135A patent/BR112018068135A2/pt unknown
- 2017-03-07 CN CN201780015630.8A patent/CN108779164B/zh active Active
- 2017-03-07 ES ES17709093T patent/ES2828086T3/es active Active
- 2017-03-07 CA CA3016752A patent/CA3016752C/en active Active
- 2017-03-07 US US16/083,508 patent/US11369660B2/en active Active
- 2017-03-07 AU AU2017230855A patent/AU2017230855B2/en active Active
-
2018
- 2018-08-28 ZA ZA2018/05743A patent/ZA201805743B/en unknown
-
2021
- 2021-04-28 AU AU2021202634A patent/AU2021202634B2/en active Active
-
2022
- 2022-06-26 US US17/849,643 patent/US12383602B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108779164A (zh) | 2018-11-09 |
| EP3426681A1 (en) | 2019-01-16 |
| CN108779164B (zh) | 2023-06-09 |
| JP2019512231A (ja) | 2019-05-16 |
| US12383602B2 (en) | 2025-08-12 |
| AU2021202634A1 (en) | 2021-05-27 |
| US11369660B2 (en) | 2022-06-28 |
| WO2017153438A1 (en) | 2017-09-14 |
| EP3426681B1 (en) | 2020-08-26 |
| EP3795588C0 (en) | 2024-12-18 |
| KR102456666B1 (ko) | 2022-10-19 |
| KR20180119605A (ko) | 2018-11-02 |
| EP3795588B1 (en) | 2024-12-18 |
| ES3009108T3 (en) | 2025-03-26 |
| US20190247466A1 (en) | 2019-08-15 |
| DK3426681T3 (da) | 2020-11-16 |
| AU2017230855A1 (en) | 2018-09-27 |
| BR112018068135A2 (pt) | 2019-01-08 |
| EP3795588A2 (en) | 2021-03-24 |
| AU2017230855B2 (en) | 2021-05-27 |
| AU2021202634B2 (en) | 2022-09-15 |
| US20220339250A1 (en) | 2022-10-27 |
| JP6980196B2 (ja) | 2021-12-15 |
| CA3016752C (en) | 2024-09-17 |
| MX392624B (es) | 2025-03-24 |
| ZA201805743B (en) | 2022-03-30 |
| CA3016752A1 (en) | 2017-09-14 |
| EP3795588A3 (en) | 2021-05-26 |
| ES2828086T3 (es) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018010836A (es) | Conformeros abiertos hla-b57. | |
| MX2020014296A (es) | Variantes de interleucina-2 y sus métodos de uso. | |
| PH12020551026A1 (en) | Fusion protein comprising il-2 protein and cd80 protein, and use thereof | |
| CY1124541T1 (el) | Πρωτεϊνες που περιλαμβανουν αμινο-τερματικες εγγυτερες τελεστικες περιοχες υπομοναδων τοξινης shiga α και περιοχες δεσμευσης τυπου-ανοσοσφαιρινων στοχευσης-κυτταρων δυναμενες της κατα συγκεκριμενο τροπο δεσμευσης cd38 | |
| WO2019099868A3 (en) | Degraders and degrons for targeted protein degradation | |
| MX2023001319A (es) | Polipeptidos condicionalmente activos. | |
| MX2018013546A (es) | Proteinas de fusion de elp para liberacion controlada y sostenida. | |
| CO2018008558A2 (es) | Moléculas que activan selectivamente las células t reguladoras para el tratamiento de enfermedades autoinmunes | |
| CY1122038T1 (el) | Ετεροδιλειτουργικοι αναστολεις των ε-σελεκτινων και των υποδοχεων χημειοκινης cxcr4 | |
| CY1123011T1 (el) | Θεραπευτικη χρηση οστικων μορφογενετικων πρωτεϊνων | |
| BR112017001940A2 (pt) | proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso | |
| MX2018010586A (es) | Nanovacuna de activacion de "sting" para inmunoterapia. | |
| BR112017005736A2 (pt) | macrociclos peptidomiméticos e formulações dos mesmos | |
| MX391015B (es) | Composiciones de nanoparticulas y usos de las mismas | |
| TW201613958A (en) | MIC-1 fusion proteins and uses thereof | |
| UY36304A (es) | Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes | |
| PE20191152A1 (es) | Anticuerpos y polipeptidos dirigidos contra cd127 | |
| BR112012018669A2 (pt) | Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo. | |
| CY1124512T1 (el) | Εμβολια καρκινου που στοχευουν καρκινικα βλαστοκυτταρα | |
| MX2016015594A (es) | Productos farmaceuticos mejorados de peptido para resistencia a la insulina. | |
| MX2020007777A (es) | Vacunas contra virus de la gripe y usos de las mismas. | |
| MX2019005979A (es) | Peptidos modificados. | |
| MX2019001136A (es) | Partículas similares a virus con recubrimiento de alta densidad para inducir la expresión de anticuerpos. | |
| AR095387A1 (es) | Proteínas específicas para el baff y para la b7rp1 y sus usos | |
| ZA202003070B (en) | Lassa vaccine |